Voloridge Investment Management LLC Purchases Shares of 177,179 uniQure (NASDAQ:QURE)

Voloridge Investment Management LLC purchased a new position in shares of uniQure (NASDAQ:QURE - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm purchased 177,179 shares of the biotechnology company's stock, valued at approximately $3,129,000. Voloridge Investment Management LLC owned about 0.36% of uniQure at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in QURE. China Universal Asset Management Co. Ltd. raised its holdings in uniQure by 9.6% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 11,062 shares of the biotechnology company's stock valued at $195,000 after acquiring an additional 969 shares in the last quarter. Palumbo Wealth Management LLC acquired a new stake in uniQure in the fourth quarter valued at about $437,000. Oppenheimer & Co. Inc. bought a new position in uniQure in the fourth quarter valued at about $320,000. Raymond James Financial Inc. acquired a new stake in shares of uniQure in the 4th quarter valued at approximately $1,951,000. Finally, Monaco Asset Management SAM acquired a new stake in shares of uniQure in the 4th quarter valued at approximately $2,414,000. 78.83% of the stock is owned by institutional investors and hedge funds.

uniQure Price Performance

NASDAQ:QURE traded down $0.34 during mid-day trading on Friday, hitting $14.56. 1,712,177 shares of the stock traded hands, compared to its average volume of 1,908,946. The business's 50-day moving average price is $12.53 and its 200 day moving average price is $12.95. The company has a market cap of $797.54 million, a PE ratio of -2.94 and a beta of 0.10. uniQure has a 12-month low of $3.73 and a 12-month high of $19.18. The company has a quick ratio of 6.51, a current ratio of 6.51 and a debt-to-equity ratio of 0.92.

uniQure (NASDAQ:QURE - Get Free Report) last issued its quarterly earnings data on Friday, May 9th. The biotechnology company reported ($0.82) EPS for the quarter, beating the consensus estimate of ($1.07) by $0.25. The company had revenue of $1.57 million during the quarter, compared to analysts' expectations of $5.93 million. uniQure had a negative net margin of 837.80% and a negative return on equity of 188.82%. On average, analysts expect that uniQure will post -3.75 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on the stock. Wells Fargo & Company dropped their price objective on shares of uniQure from $35.00 to $30.00 and set an "equal weight" rating for the company in a report on Friday, February 28th. HC Wainwright restated a "buy" rating and set a $70.00 price target on shares of uniQure in a report on Thursday. Chardan Capital reaffirmed a "buy" rating and set a $38.00 price objective on shares of uniQure in a research report on Friday. Wall Street Zen raised shares of uniQure from a "sell" rating to a "hold" rating in a research report on Saturday, May 24th. Finally, Guggenheim reissued a "buy" rating and issued a $28.00 price target on shares of uniQure in a research report on Monday, May 12th. Four research analysts have rated the stock with a hold rating, six have given a buy rating and two have given a strong buy rating to the company's stock. Based on data from MarketBeat.com, uniQure has an average rating of "Moderate Buy" and an average target price of $37.82.

Insider Activity at uniQure

In related news, CEO Matthew C. Kapusta sold 28,341 shares of the company's stock in a transaction that occurred on Tuesday, March 4th. The shares were sold at an average price of $10.29, for a total value of $291,628.89. Following the transaction, the chief executive officer now directly owns 651,454 shares in the company, valued at approximately $6,703,461.66. This represents a 4.17% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Christian Klemt sold 10,438 shares of the company's stock in a transaction that occurred on Tuesday, March 4th. The stock was sold at an average price of $10.29, for a total transaction of $107,407.02. Following the completion of the transaction, the chief financial officer now owns 217,730 shares in the company, valued at approximately $2,240,441.70. This trade represents a 4.57% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 40,129 shares of company stock valued at $412,927. Corporate insiders own 4.74% of the company's stock.

uniQure Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.